相关实验视频
Updated: Jan 17, 2026

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.0K
在生物经验丰富的患者中,开发和外部验证一种多变量预测模型,用于进展到难以治疗的类风湿关节炎
Misti L Paudel1,2, Nancy Shadick1,2, Michael Weinblatt1,2
1Brigham and Women's Hospital, Boston, Massachusetts.
Arthritis care & research
|September 22, 2025
概括
一个新的模型通过分析患者数据,可以适度预测难以治疗的类风湿性关节炎 (D2T-RA). 疼痛和疲劳等症状恶化是识别D2T-RA风险患者的关键指标.
科学领域:
- 类风湿病学 类风湿病学
- 临床预测建模临床预测建模
- 生物统计学 生物统计学
背景情况:
- 类风湿性关节炎 (RA) 影响全球数以百万计的人,其中有一部分人经历了治疗耐药性.
- 难以治疗的RA (D2T-RA) 影响大约20%的患者,需要更好的风险分层工具.
- 目前的临床实践缺乏验证的工具来识别具有D2T-RA高风险的RA患者.
研究的目的:
- 开发和验证一个多变量预测模型,用于识别患有D2T-RA进展风险的患者.
- 使用欧洲风湿病学协会联盟 (EULAR) 2021年标准来定义D2T-RA.
主要方法:
- 利用来自两个独立的观察RA队列的数据进行模型开发和外部验证.
- 使用随机生存森林对参与者启动他们的第一个生物和/或向合成疾病修饰性抗风湿药物 (b/tsDMARD).
- 在一个单独的患者队列中验证了该模型,该队列是开始或切换b/tsDMARD疗法的患者.
主要成果:
- 导出队列包括700名患者 (16%D2T-RA),验证队列包括2070名患者 (28%D2T-RA).
- 该模型实现了适度的预测能力,C指数值为0.643 (衍生) 和0.620 (验证).
- D2T-RA的关键预测因素包括功能状况恶化,疼痛,疲劳和全球疾病活动.
结论:
- 开发的模型显示了适度的歧视和校准,用于预测D2T-RA.
- 准确预测D2T-RA仍然具有挑战性,这表明需要改进预测模型.
- 未来的研究应该探索结合额外的生物标志物来提高预测的准确性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
500
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
500
Rheumatic Heart Disease III: Medical Management
289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493

